As the Fed was meeting to consider cutting interest rates, it lost control of the very benchmark rate that it manages.Market Insiderread more
Activists with Black Lives Matter, who met privately with Buttigieg in the weeks after police shot and killed Eric Logan, say the 37-year-old mayor brushed off their concerns...2020 Electionsread more
DoubleLine CEO Jeffrey Gundlach said the Federal Reserve might need to embark on quantitative easing to increase the money supply.Marketsread more
Wall Street economists think the Fed will cut rates by 25 basis points at its September meeting but have differing views about what will happen in the future.Marketsread more
Trump said he "is revoking" a federal waiver that allowed the state to craft its own rules on greenhouse gas emissions from vehicles.Politicsread more
FedEx CEO Fred Smith mentioned Amazon as one of his competitors during Tuesday's earnings call, a shift in stance for a company that's long downplayed Amazon's move into the...Technologyread more
DoubleLine Capital's Jeffrey Gundlach spoke to CNBC on Wednesday ahead of the Federal Reserve's decision on interest rates.Marketsread more
Shares of Roku fell on Wednesday after Comcast announced a new deal on its connected boxes and Facebook launched a new Portal TV device.Technologyread more
J.P. Morgan Chase chief Dimon says he doesn't think the U.S. is close to recession and called the Fed's Powell "a quality human."Marketsread more
Check out the companies making headlines in midday trading.Market Insiderread more
Drone and missile debris recovered by investigators at the Saudi Aramco attack site is proof of Iranian culpability, a Saudi defense ministry representative told media on...World Politicsread more
Shares of Sarepta Therapeutics surged another 13 percent in Tuesday trade after closing nearly 74 percent higher Monday on government approval of its muscular dystrophy drug eteplirsen.
The drug was granted accelerated approval by the Food and Drug Administration and it treats patients with Duchenne muscular dystrophy, a rare, genetic muscle-wasting disease.
Late Monday, the pharmaceutical firm announced in a conference call that the net annual price of the drug will be $300,000.
Edward Tenthoff, senior research analyst at Piper Jaffray, estimated the gross annual price of the drug is about $666,000 a year. While he said it wasn't clear what customer response to the drug pricing would be, Tenthoff said he expected "there will be pushback."
Sarepta did not immediately return CNBC's request for comment.
Tenthoff maintained an "overweight" rating and $64 price target, which would represent a more than 30 percent upside from Monday's close. With the gains of the week so far, Sarepta shares are trading more than 40 percent higher year-to-date.